| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Jimenez Balarezo, Moraima |
| dc.contributor.author | Roldan Galvan, Elisa |
| dc.contributor.author | Fernandez Naval, Candela |
| dc.contributor.author | Peralta Garzon, Soraya |
| dc.contributor.author | Pujadas, Gemma |
| dc.contributor.author | Hernández Buñuel, Cristina |
| dc.contributor.author | Gironella Mesa, Mercedes |
| dc.contributor.author | Orti Pascual, Guillem |
| dc.contributor.author | Barba Suñol, Pere |
| dc.contributor.author | Pumarola Suñé, Tomàs |
| dc.contributor.author | Cabirta Touzon, Alba |
| dc.contributor.author | Catalá, Eva |
| dc.contributor.author | Valentin, Mercedes |
| dc.contributor.author | Orfao, Alberto |
| dc.contributor.author | González, Marcos |
| dc.contributor.author | Ruiz Camps, Isabel |
| dc.contributor.author | Valcarcel Ferreiras, David |
| dc.contributor.author | Bosch, Francesc |
| dc.contributor.author | Hernández González, Manuel |
| dc.contributor.author | Crespo Maull, Marta |
| dc.contributor.author | Esperalba Esquerra, Juliana |
| dc.contributor.author | Villacampa Javierre, Guillermo |
| dc.contributor.author | Marin Niebla, Ana |
| dc.contributor.author | Martínez Gallo, Mónica |
| dc.contributor.author | Fox, Maria Laura |
| dc.contributor.author | Campins Martí, Magda |
| dc.contributor.author | Abrisqueta, Pau |
| dc.contributor.author | Medina-Gil, Daniel |
| dc.contributor.author | Pagès Geli, Carlota |
| dc.date.accessioned | 2022-12-09T08:56:25Z |
| dc.date.available | 2022-12-09T08:56:25Z |
| dc.date.issued | 2022-02-08 |
| dc.identifier.citation | Jimenez M, Roldan E, Fernandez-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022 Feb 8;6(3):774–84. |
| dc.identifier.issn | 2473-9537 |
| dc.identifier.uri | https://hdl.handle.net/11351/8614 |
| dc.description | Immunobiology; Immunotherapy |
| dc.description.abstract | Recent studies have shown a suboptimal humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients diagnosed with hematologic malignancies; however, data about cellular immunogenicity are scarce. The aim of this study was to evaluate both the humoral and cellular immunogenicity 1 month after the second dose of the mRNA-1273 vaccine. Antibody titers were measured by using the Elecsys and LIAISON anti–SARS-CoV-2 S assays, and T-cell response was assessed by using interferon-γ release immunoassay technology. Overall, 76.3% (184 of 241) of patients developed humoral immunity, and the cellular response rate was 79% (184 of 233). Hypogammaglobulinemia, lymphopenia, active hematologic treatment, and anti-CD20 therapy during the previous 6 months were associated with an inferior humoral response. Conversely, age >65 years, active disease, lymphopenia, and immunosuppressive treatment of graft-versus-host disease (GVHD) were associated with an impaired cellular response. A significant dissociation between the humoral and cellular responses was observed in patients treated with anti-CD20 therapy (the humoral response was 17.5%, whereas the cellular response was 71.1%). In these patients, B-cell aplasia was confirmed while T-cell counts were preserved. In contrast, humoral response was observed in 77.3% of patients undergoing immunosuppressive treatment of GVHD, whereas only 52.4% had a cellular response. The cellular and humoral responses to the SARS-CoV-2 mRNA-1273 vaccine in patients with hematologic malignancies are highly influenced by the presence of treatments such as anti-CD20 therapy and immunosuppressive agents. This observation has implications for the further management of these patients. |
| dc.language.iso | eng |
| dc.publisher | American Society of Hematology |
| dc.relation.ispartofseries | Blood Advances;6(3) |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.source | Scientia |
| dc.subject | COVID-19 (Malaltia) - Vacunació |
| dc.subject | Immunoglobulines |
| dc.subject | Sang - Malalties |
| dc.subject.mesh | Hematologic Neoplasms |
| dc.subject.mesh | Coronavirus Infections |
| dc.subject.mesh | Immunogenicity, Vaccine |
| dc.title | Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1182/bloodadvances.2021006101 |
| dc.subject.decs | neoplasias hematológicas |
| dc.subject.decs | infecciones por Coronavirus |
| dc.subject.decs | inmunogenicidad vacunal |
| dc.relation.publishversion | https://doi.org/10.1182/bloodadvances.2021006101 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Jiménez M, Roldán E, Gironella M, Fox L, Orti G, Barba P, Valcárcel D, Bosch F, Abrisqueta P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fernández-Naval C, Pumarola T, Esperalba J] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Villacampa G] Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Martinez-Gallo M, Hernández M] Servei d’Immunologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Crespo M] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Cabirta A, Catalá E, Valentín M, Marín-Niebla A] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Orfao A] Department of Medicine and Cytometry General ServiceNucleus, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain. [González M] Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC–CB16/12/00233 and Center for Cancer Research–IBMCC (USAL-CSIC), Salamanca, Spain. [Campins M] Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ruiz-Camps I] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain |
| dc.identifier.pmid | 34844263 |
| dc.identifier.wos | 000754263400007 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |